# Phase 1 Precursor Cell: 59 recruiting (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 59 trials in phase 1 for Precursor Cell Lymphoblastic Leukemia-Lymphoma that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma trials: 59 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1/precursor-cell-lymphoblastic-leukemia-lymphoma

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 59
- Recruiting or not yet: 59
- Read on: November 19, 2026

## Trials

The 25 newest of 59, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 6, 2026 | NCT07923071 | A Study to Assess the Pharmacokinetics and Safety of Revumenib in Participants With Advanced Cancer and Hepatic or Renal Impairment | Syndax Pharmaceuticals | Phase 1 | Not yet recruiting | Relapsed/Refractory (R/R) Hematologic Malignancies, Acute Leukemia, Refractory Leukemia, Relapsed Leukemia | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07923071) |
| October 23, 2026 | NCT07891468 | huCART19-IL18-CD428z Cells for the Treatment of Patients With HIV With CD19+ Cancers | University of Pennsylvania | Phase 1 | Not yet recruiting | Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, Richter's Transformation | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07891468) |
| October 20, 2026 | NCT07883941 | Phase I Safety Clinical Trial of Anti-CD19 CAR-T Therapy COL01 for the Treatment of Adults With Relapsed or Refractory B-cell Lymphoid... | Sponsor not shown (see the record) | Phase 1 | Not yet recruiting | Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia, Lymphoid Malignancies, Diffuse Large B Cell Lymphoma... | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07883941) |
| May 29, 2026 | NCT07616089 | Phase I Study of FXS0683 in the Treatment of Blood Tumors | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Phase 1 | Recruiting | B-Cell Lymphoma, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Acute Lymphoblastic Leukemia | 228 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07616089) |
| May 29, 2026 | NCT07614022 | A Study of LP-118 In Combination With Ponatinib, Dexamethasone And Blinatumomab For Adults With Newly-Diagnosed, BCR::ABL1-Positive Acute... | Wake Forest University Health Sciences | Phase 1 | Recruiting | Philadelphia Positive Acute Lymphoblastic Leukemia | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07614022) |
| May 14, 2026 | NCT07586618 | First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic... | Allterum Therapeutics, Inc | Phase 1 | Recruiting | Lymphoblastic Lymphoma, Acute Lymphoblastic Leukemia ALL | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07586618) |
| May 7, 2026 | NCT07573111 | Study of QUAIL-100 in Pediatric and Young Adult Participants With High-Risk Hematologic Malignancies Who Have Received a Hematopoietic Stem... | Laguna Biotherapeutics, Inc. | Phase 1 | Recruiting | Acute Leukemia, Myelodysplastic Syndrome | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07573111) |
| May 7, 2026 | NCT07572136 | Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing... | National Cancer Institute (NCI) | Phase 1 | Recruiting | B-All, Acute Lymphoblastic Leukemia | 57 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07572136) |
| May 4, 2026 | NCT07565220 | Thiotepa-based Conditioning Regimen With De-escalated Post-graft Cyclophosphamide for Allogeneic Stem Cell Transplantation in Hematologic... | Sponsor not shown (see the record) | Phase 1 | Recruiting | Acute Lymphocytic Leukemia (ALL), Acute Myeloid Leukemia (AML), Acute Leukemia, Myelodysplastic Syndrome(MDS)... | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07565220) |
| April 8, 2026 | NCT07518654 | Phase I Clinical Trial of ThINKK Adoptive Immunotherapy After Allogeneic Hematopoietic Transplantation in Children With Leukemia or... | Sponsor not shown (see the record) | Phase 1 | Not yet recruiting | Leukaemia (Acute Lymphoblastic), Leukaemia (Acute Myeloid), Neuroblastoma, Neuroblastoma, Metastatic, Leukaemia... | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07518654) |
| January 22, 2026 | NCT07361029 | CD19 Chimeric Antigen Receptor (CAR) T Cells in Adults With Relapsed/Refractory CD19 Positive Acute Lymphoblastic Leukemia | King Faisal Specialist Hospital & Research Center | Phase 1 | Recruiting | Relapsed Refractory Acute Lymphoblastic Leukemia | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07361029) |
| December 16, 2025 | NCT07284927 | Clinical Study of LV009 Injection for the Treatment of Hematologic and Lymphoid Malignancies | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Phase 1 | Recruiting | Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07284927) |
| December 16, 2025 | NCT07283640 | A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic Leukemia | M.D. Anderson Cancer Center | Phase 1 | Not yet recruiting | Blinatumomab, Revumenib, Lymphoblastic Leukemia, KMT2A-rearranged | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07283640) |
| December 2, 2025 | NCT07257419 | CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for... | St. Jude Children's Research Hospital | Phase 1 | Recruiting | Relapsed Pediatric ALL, Hematopoietic Cell Transplantation, Hematologic Malignancy | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07257419) |
| November 28, 2025 | NCT07254793 | Prophylactic DLI-X for Leukemia Relapse After HCT | University of Arizona | Phase 1 | Recruiting | Acute Lymphoid Leukemia, Acute Myeloid Leukemia, Acute Undifferentiated Leukemia (AUL), Myelodysplastic Syndrome... | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07254793) |
| September 10, 2025 | NCT07166549 | Bispecific CAR T Cells for B-cell Malignancies (BaseCAR-01 Trial) | University Hospital, Basel, Switzerland | Phase 1 | Not yet recruiting | B Cell Malignancies, B-cell Leukemia, B Cell Lymphoma, Bispecific Chimeric Antigen Receptor (CAR) T Cells, Relapsed or... | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07166549) |
| August 7, 2025 | NCT07108868 | A Phase I Dose Finding Study of MB-CART2219.1 | University Hospital Tuebingen | Phase 1 | Recruiting | Lymphoma, CLL, Acute Lymphoblastic Leukemia, Pediatric | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07108868) |
| July 15, 2025 | NCT07066397 | A Phase 1 Study of FIT-CD19-CAR-T Cells in R/R B-ALL | TriArm Therapeutics (Taiwan) Limited | Phase 1 | Recruiting | Acute Lymphoblastic Leukemia | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07066397) |
| June 13, 2025 | NCT07020533 | A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing... | City of Hope Medical Center | Phase 1 | Recruiting | Accelerated Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia... | 46 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07020533) |
| April 1, 2025 | NCT06904066 | Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic... | National Cancer Institute (NCI) | Phase 1 | Recruiting | Malignancy, Hematologic, Neoplasms, Hematologic, Neoplasms, Hematopoietic, Blood Cancer, Hematological Neoplasms... | 86 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06904066) |
| March 25, 2025 | NCT06894693 | A Phase I Clinical Trial of RS001 in Patients with Relapsed/Refractory B-Cell Malignancies | Guangdong Ruishun Biotech Co., Ltd | Phase 1 | Not yet recruiting | B-cell Non-Hodgkin's Lymphoma, Acute Lymphoblastic Leukemia | 13 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06894693) |
| January 16, 2025 | NCT06777979 | CD19-CD22-Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy for Pediatric Patients With Acute Lymphoblastic Leukemia | St. Jude Children's Research Hospital | Phase 1 | Recruiting | Acute Lymphoblastic Leukemia, Recurrent Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06777979) |
| December 31, 2024 | NCT06752785 | CD19/CD22 CAR-T Cell Therapy in MRD-Positive B-lineage Acute Lymphoblastic Leukemia in Children. | Guangzhou Women and Children's Medical Center | Phase 1 | Recruiting | Acute Lymphoblastic Leukemia | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06752785) |
| November 29, 2024 | NCT06709469 | Phase I Clinical Trial of CART Cell Therapy for Refractory/Relapsed Acute Lymphoblastic Leukemia in Children, Adolescents and Young Adults | Instituto de Investigación Hospital Universitario La Paz | Phase 1 | Recruiting | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06709469) |
| October 15, 2024 | NCT06641024 | Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/ Refractory B-ALL | Chongqing Precision Biotech Co., Ltd | Phase 1 | Not yet recruiting | Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoblastic Leukemia | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06641024) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| St. Jude Children's Research Hospital | 4 |
| City of Hope Medical Center | 3 |
| National Cancer Institute (NCI) | 3 |
| Stanford University | 2 |
| [PersonGen BioTherapeutics (Suzhou) Co., Ltd.](https://specstream.ai/data/clinical-trials/company/persongen-biotherapeutics-suzhou-co-ltd) | 1 |
| H. Lee Moffitt Cancer Center and Research Institute | 1 |
| University of Utah | 1 |
| University of Chicago | 1 |
| Fifth Affiliated Hospital, Sun Yat-Sen University | 1 |
| Therapeutic Advances in Childhood Leukemia Consortium | 1 |
| [Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.](https://specstream.ai/data/clinical-trials/company/shanghai-fosun-pharmaceutical-industrial-development-co-ltd) | 1 |
| University of Oklahoma | 1 |
| University College, London | 1 |
| University of Colorado, Denver | 1 |
| Fred Hutchinson Cancer Center | 1 |
| King Faisal Specialist Hospital & Research Center | 1 |
| Autolus Limited | 1 |
| Baylor College of Medicine | 1 |
| M.D. Anderson Cancer Center | 1 |
| [Ascentage Pharma Group Inc.](https://specstream.ai/data/clinical-trials/company/ascentage-pharma-group-inc) | 1 |
| Institute of Hematology & Blood Diseases Hospital, China | 1 |
| [Chongqing Precision Biotech Co., Ltd](https://specstream.ai/data/clinical-trials/company/chongqing-precision-biotech-co-ltd) | 1 |
| Wake Forest University Health Sciences | 1 |
| Instituto de Investigación Hospital Universitario La Paz | 1 |
| Newave Pharmaceutical Inc | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 39 |
| China | 9 |
| United Kingdom | 2 |
| Canada | 2 |
| Spain | 2 |
| Australia | 1 |
| Saudi Arabia | 1 |
| Brazil | 1 |
| Switzerland | 1 |
| Germany | 1 |
| Taiwan | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Banks and credit unions in the United States](https://specstream.ai/data/businesses/banks-and-credit-unions/united-states)
- [Israeli restaurants in the United States](https://specstream.ai/data/businesses/israeli-restaurants/united-states)
- [TV service providers in the United States](https://specstream.ai/data/businesses/tv-service-providers/united-states)
- [Environmental services in the United States](https://specstream.ai/data/businesses/environmental-services/united-states)
- [Property management companies in the United States](https://specstream.ai/data/businesses/property-management-companies/united-states)
- [Business brokers in the United States](https://specstream.ai/data/businesses/business-brokers/united-states)
